Cervical carcinoma rates among young females in the United States
- PMID: 23090530
- PMCID: PMC4540330
- DOI: 10.1097/aog.0b013e31826e4609
Cervical carcinoma rates among young females in the United States
Abstract
Objective: All national organizations now recommend that women be screened for cervical cancer beginning at age 21 years, regardless of age of sexual initiation; however, studies have shown that providers continue to screen much earlier than recommended. Two federal cancer surveillance systems were used to quantify the burden of invasive cervical carcinoma among women younger than 40 years of age.
Methods: We examined combined data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program covering 92% of the U.S. population. We calculated the age-adjusted incidence of cervical carcinoma among women younger than age 40 years by age, race, ethnicity, and histology for the time period of 1999-2008.
Results: For women younger than age 40 years, 78% of the cervical cancer cases were diagnosed in women aged 30-39, 21% were diagnosed in women 20-29 years of age, and 1% was diagnosed in women younger than age 20 years. There was an average of 3,063 cases of invasive cervical carcinomas annually from 1999 through 2008, with an average of 14 carcinomas per year (rate of 0.15 per 100,000 females) among those aged 15-19 years, and 125 carcinomas per year (rate of 1.4 per 100,000 females) among those aged 20-24 years.
Conclusion: Cervical cancer is very rare in young women. Widespread implementation of Pap testing over the past four decades has detected very few cases of cervical cancer in women younger than 25 while potentially causing harm with unnecessary follow-up interventions.
Level of evidence: III.
Figures
Similar articles
-
Burden of cervical cancer in the United States, 1998-2003.Cancer. 2008 Nov 15;113(10 Suppl):2855-64. doi: 10.1002/cncr.23756. Cancer. 2008. PMID: 18980204
-
Cervical cancer incidence in a prevaccine era in the United States, 1998-2002.Obstet Gynecol. 2007 Feb;109(2 Pt 1):360-70. doi: 10.1097/01.AOG.0000254165.92653.e8. Obstet Gynecol. 2007. PMID: 17267837
-
Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study.Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):30-37. doi: 10.1158/1055-9965.EPI-20-0846. Epub 2020 Oct 20. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33082207 Free PMC article.
-
Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985-2003.Cancer. 2008 Nov 15;113(10 Suppl):2946-54. doi: 10.1002/cncr.23747. Cancer. 2008. PMID: 18980278
-
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 11-05157-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 11-05157-EF-1. PMID: 22553886 Free Books & Documents. Review.
Cited by
-
Impact of Various Treatment Modalities on Long-Term Quality of Life in Cervical Cancer Survivors.Cureus. 2024 Sep 4;16(9):e68642. doi: 10.7759/cureus.68642. eCollection 2024 Sep. Cureus. 2024. PMID: 39371786 Free PMC article.
-
Validation of an on-chip p16ink4a/Ki-67 dual immunostaining cervical cytology system using microfluidic device technology.Sci Rep. 2023 Oct 10;13(1):17052. doi: 10.1038/s41598-023-44273-6. Sci Rep. 2023. PMID: 37816765 Free PMC article.
-
Potential Effects of Age-Based Changes in Screening Guidelines on the Identification of Women at Risk for Developing Cervical Cancer.Cancer Prev Res (Phila). 2023 Jan 18:OF1-OF10. doi: 10.1158/1940-6207.CAPR-22-0426. Online ahead of print. Cancer Prev Res (Phila). 2023. PMID: 36657016 Free PMC article.
-
miR-218-5p/RUNX2 Axis Positively Regulates Proliferation and Is Associated with Poor Prognosis in Cervical Cancer.Int J Mol Sci. 2022 Jun 23;23(13):6993. doi: 10.3390/ijms23136993. Int J Mol Sci. 2022. PMID: 35805994 Free PMC article.
-
Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.Viruses. 2022 Apr 5;14(4):757. doi: 10.3390/v14040757. Viruses. 2022. PMID: 35458487 Free PMC article.
References
-
- U. S. Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. 2012 Available at: http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcan.... Retrieved April 25, 2012. - PubMed
-
- Cervical cytology screening. ACOG Practice Bulletin No. 109. American College of Obstetricians and Gynecologist. Obstet Gynecol. 2009;114:1409–20. - PubMed
-
- Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:698–705. - PubMed
-
- Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;137:516–42. - PubMed
-
- Hildesheim A, Hadjimichael O, Schwartz PE, Wheeler CM, Barnes W, Lowell DM, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol. 1999;180(3 Pt 1):571–7. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
